This segment focuses on the research, development, and clinical trials of allogeneic CAR T-cell therapies (AlloCAR T™) for various hematologic malignancies and solid tumors. Allogene's AlloCAR T™ platform aims to provide off-the-shelf, readily available cell therapies that can overcome the limitations of autologous CAR T-cell therapies, such as manufacturing complexities and patient-specific variability. Research activities include optimizing CAR design, enhancing T-cell persistence, and reducing the risk of graft-versus-host disease (GvHD). The segment leverages gene editing technologies, such as CRISPR, to modify T-cells and improve their safety and efficacy. Clinical trials are conducted to evaluate the safety and efficacy of AlloCAR T™ candidates in patients with relapsed/refractory cancers. The ultimate goal is to provide accessible and effective CAR T-cell therapies to a broader patient population, improving outcomes and quality of life.

This segment encompasses Allogene's extensive clinical trial programs and research initiatives aimed at advancing its pipeline of AlloCAR T cell therapies. The focus is on conducting rigorous clinical studies to evaluate the safety, efficacy, and optimal dosing regimens of various AlloCAR T candidates across different cancer types. Research activities include preclinical studies, Phase 1, Phase 2, and potentially Phase 3 clinical trials. Technologies and methodologies used involve advanced cell engineering, gene editing, and sophisticated data analysis to monitor patient responses and identify biomarkers predictive of treatment success. Therapeutic areas covered include hematologic malignancies such as lymphoma and multiple myeloma, as well as solid tumors. The patient impact is significant, as these trials offer hope for patients with relapsed or refractory cancers who have exhausted other treatment options. Future opportunities include expanding clinical trials to new indications and developing novel AlloCAR T constructs with enhanced anti-tumor activity.